Wikidata

(Q61909412)

English

Study of Carfilzomib, Daratumumab and Dexamethasone for Patients With Relapsed and/or Refractory Multiple Myeloma.

clinical trial

In more languages

Statements

short name
CANDOR (English)
0 references
title
A Randomized, Open-label, Phase 3 Study Comparing Carfilzomib, Dexamethasone, and Daratumumab to Carfilzomib and Dexamethasone for the Treatment of Patients With Relapsed or Refractory Multiple Myeloma CANDOR Study of Carfilzomib ANd Daratumumab fOr Relapsed Myeloma (English)
0 references
sponsor
Amgen
0 references
country
Australia
0 references
Austria
0 references
Belgium
0 references
Bulgaria
0 references
Canada
0 references
France
0 references
Greece
0 references
Hungary
0 references
Japan
0 references
Poland
0 references
Romania
0 references
Spain
0 references
Taiwan
0 references
Turkey
0 references
United Kingdom
0 references
start time
13 June 2017
0 references
end time
24 June 2019
0 references
number of participants
466
0 references
minimum age
18 year
0 references

Identifiers

 
edit
    edit
      edit
        edit
          edit
            edit
              edit
                edit
                  edit
                    Retrieved from "https://www.wikidata.org/w/index.php?title=Q61909412&oldid=2109168927"